ENSG Stock Analysis: The Ensign | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 10.641m USD | 12M Return: 2.1% | US29358P1012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.7M
EPS Trend: 99.4%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
The Ensign Group (ENSG) is a U.S. healthcare company that operates skilled nursing facilities, senior living communities, and rehabilitative services across 16 states, with a footprint concentrated in the West, South, and Midwest.
The company operates through two segments. The Skilled Services segment provides short- and long-term nursing care for patients with chronic conditions or prolonged illness, along with specialty offerings such as on-site dialysis, ventilator care, and cardiac and pulmonary management. The Standard Bearer segment functions as a real estate operation, leasing post-acute care properties to third-party healthcare operators-an unusual structure within the Health Care Facilities sub-industry that separates property ownership from facility operations.
In addition, ENSG runs senior living units and provides ancillary services including digital x-ray, ultrasound, electrocardiograms, sub-acute care, respiratory services, long-term care pharmacy, patient transportation, and mobile diagnostics. Skilled nursing operators in this segment typically rely on Medicare and Medicaid reimbursement, making them sensitive to changes in federal and state payment policies. The company was incorporated in 1999 and is headquartered in San Juan Capistrano, California.
- Skilled nursing occupancy and rate growth boost revenue
- Medicare and Medicaid reimbursement changes impact revenue
- Acquisition pipeline expansion fuels facility count growth
| Net Income: 399.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.96 > 1.0 |
| NWC/Revenue: 3.38% < 20% (prev 7.90%; Δ -4.51% < -1%) |
| CFO/TA 0.12 > 3% & CFO 695.7m > Net Income 399.1m |
| Net Debt (3.98b) to EBITDA (661.2m): 6.03 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.3m) vs 12m ago 0.59% < -2% |
| Gross Margin: 14.73% > 18% (prev 15.65%; Δ -0.92% > 0.5%) |
| Asset Turnover: 101.1% > 50% (prev 92.40%; Δ 8.70% > 0%) |
| Interest Coverage Ratio: 66.70 > 6 (EBIT TTM 540.6m / Interest Expense TTM 8.11m) |
| A: 0.03 (Total Current Assets 1.15b - Total Current Liabilities 962.9m) / Total Assets 6.00b |
| B: 0.34 (Retained Earnings 2.05b / Total Assets 6.00b) |
| C: 0.10 (EBIT TTM 540.6m / Avg Total Assets 5.61b) |
| D: 0.75 (Book Value of Equity 2.56b / Total Liabilities 3.43b) |
| Altman-Z'' = 2.75 = A |
| DSRI: 0.92 (Receivables 664.8m/612.7m, Revenue 5.67b/4.83b) |
| GMI: 1.06 (GM 15.65% / 14.73%) |
| AQI: 1.04 (AQ_t 0.07 / AQ_t-1 0.07) |
| SGI: 1.17 (Revenue 5.67b / 4.83b) |
| TATA: -0.05 (NI 399.1m - CFO 695.7m) / TA 6.00b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of November 12, 2026, the stock is trading at USD 186.19 with a total of 244,344 shares traded. Over the past week, the price has changed by +1.58%, over one month by +6.42%, over three months by +0.66% and over the past year by +2.12%.
Current recommended Stop Loss: 174.50 (which is 6.3% or 2.3 ATR below the current price).
The Ensign has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy ENSG.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 225.8 | 21.3% |
P/E Trailing = 28.0169
P/E Forward = 22.0264
P/S = 1.8753
P/B = 4.2933
P/EG = 1.4668
Revenue TTM = 5.67b USD
EBIT TTM = 540.6m USD
EBITDA TTM = 661.2m USD
Long Term Debt = 194.7m USD (from longTermDebt, last quarter)
Short Term Debt = 124.4m USD (from shortTermDebt, last quarter)
Debt = 4.38b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.09b
Net Debt = 3.98b USD (calculated: Debt 4.38b - CCE 391.7m)
Enterprise Value = 14.6b USD (10.6b + Debt 4.38b - CCE 391.7m)
Interest Coverage Ratio = 66.70 (Ebit TTM 540.6m / Interest Expense TTM 8.11m)
EV/FCF = 28.68x (Enterprise Value 14.6b / FCF TTM 509.9m)
FCF Yield = 3.49% (FCF TTM 509.9m / Enterprise Value 14.6b)
FCF Margin = 8.99% (FCF TTM 509.9m / Revenue TTM 5.67b)
Net Margin = 7.03% (Net Income TTM 399.1m / Revenue TTM 5.67b)
Gross Margin = 14.73% ((Revenue TTM 5.67b - Cost of Revenue TTM 4.84b) / Revenue TTM)
Gross Margin QoQ = 16.86% (prev 16.65%)
Tobins Q-Ratio = 2.44 (Enterprise Value 14.6b / Total Assets 6.00b)
Interest Expense / Debt = 0.19% (Interest Expense 8.11m / Debt 4.38b)
Taxrate = 24.98% (133.0m / 532.5m)
NOPAT = 405.6m (EBIT 540.6m * (1 - 24.98%))
Current Ratio = 1.20 (Total Current Assets 1.15b / Total Current Liabilities 962.9m)
Debt / Equity = 1.71 (Debt 4.38b / totalStockholderEquity, last quarter 2.56b)
Debt / EBITDA = 6.03 (Net Debt 3.98b / EBITDA 661.2m)
Debt / FCF = 7.81 (Net Debt 3.98b / FCF TTM 509.9m)
Total Stockholder Equity = 2.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.11% (Net Income 399.1m / Total Assets 6.00b)
RoE = 16.63% (Net Income TTM 399.1m / Total Stockholder Equity 2.40b)
RoCE = 20.83% (EBIT 540.6m / Capital Employed (Equity 2.40b + L.T.Debt 194.7m))
RoIC = 8.32% (NOPAT 405.6m / Invested Capital 4.88b)
WACC = 4.48% (E(10.6b)/V(15.0b) * Re(6.26%) + D(4.38b)/V(15.0b) * Rd(0.19%) * (1-Tc(0.25)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.50 | Cagr: 0.98%
[DCF] Terminal Value 77.97% ; FCFF base≈421.8m ; Y1≈483.5m ; Y5≈711.5m
[DCF] Fair Price = 115.2 (EV 10.7b - Net Debt 3.98b = Equity 6.72b / Shares 58.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.38 | EPS CAGR: 16.81% | SUE: 0.65 | # QB: 0
Revenue Correlation: 99.83 | Revenue CAGR: 17.04% | SUE: -2.57 | # QB: -1
EPS current Quarter (2027-03-31): EPS=2.13 | Chg30d=+1.24% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=7.98 | Chg30d=+2.18% | Revisions=+25% | GrowthEPS=+21.5% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=8.77 | Chg30d=+2.55% | Revisions=+40% | GrowthEPS=+9.9% | GrowthRev=+12.7%
[Analyst] Revisions Ratio: +57% (up=4, down=0)